Medicus Pharma (MDCX) Liabilities and Shareholders Equity (2023 - 2026)
Medicus Pharma's (MDCX) quarterly Liabilities and Shareholders Equity came in at $10.1 million in Q4 2025, up 78.18% YoY from $5.6 million in Q4 2024, and up 0.84% on a QoQ basis from $10.0 million in Q3 2025.
Medicus Pharma (MDCX) Liabilities and Shareholders Equity (2023 - 2026) Analysis & Trends
Medicus Pharma (MDCX) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $10.1 million in Q4 2025.
- Quarterly Liabilities and Shareholders Equity rose 78.18% year-over-year to $10.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $37.6 million (up 566.41% YoY) and the FY2025 annual result came in at $10.1 million, up 78.18% from the prior year.
- Liabilities and Shareholders Equity improved to $10.1 million in Q4 2025, from $10.0 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $11.9 million in Q2 2025 to a low of $1.9 million in Q4 2023.
- A 3-year average of $7.5 million and a median of $7.8 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 198.29% — and 2025, when it soared 78.18%.
- Tracing MDCX's Liabilities and Shareholders Equity over 3 years: stood at $1.9 million in 2023, then surged by 198.29% to $5.6 million in 2024, then surged by 78.18% to $10.1 million in 2025.
- The last three Liabilities and Shareholders Equity figures came in at $10.1 million (Q4 2025), $10.0 million (Q3 2025), and $11.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 82.83 Bn |
| 10 | Medicus Pharma | 14.88 Mn | -298,205.43 | - | 27.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.12 Mn |
| Dec 31, 2025 | 10.06 Mn |
| Sep 30, 2025 | 9.98 Mn |
| Jun 30, 2025 | 11.93 Mn |
| Mar 31, 2025 | 5.66 Mn |
| Dec 31, 2024 | 5.65 Mn |
| Dec 31, 2023 | 1.89 Mn |